G432(P) A strategy for reducing planned stabilization admissions from two weeks to one

Abstract

Median age (range) at start of treatment was 14.8 yrs (9.7,18.0) and this remained unchanged during 2011-2018 (p=0.543). GnRHa was discontinued in 5/65 (8%) YP [1 (2%) birth-assigned female, 4 (19%) birthassigned males, p=0.018] after a median (range) duration of 0.8 yrs (0.5,1.5). Twenty-two YP started gender-affirming hormones (17 birth-assigned females, 5 birth-assigned males). Median age (range) at start was 16.21 yrs (16.04,17.13). In one YP, this was discontinued, after a period of 0.33 yrs. Overall, 3/74 (4%) YP (1 birth-assigned female, 2 birth-assigned males) were no longer experiencing gender dysphoria during the period of attending paediatric endocrinology and discontinued treatment. Conclusion There has been a marked increase from 2016 onward in prevalence of YP with GD referred to paediatric endocrinology, requiring an evolution in the structure of a whole service. Pursuit of fertility preservation has been poor and requires closer consideration.